Register on prospective evaluation of therapy-free remission in chronic myeloid leukaemia with the aim of identifying prognostic factors - CML-TFR-Register

niversität Heidelberg0 个研究点目标入组 200 人开始时间: 2022年6月3日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. informed written consent of the patient(s).
•2. Only adult patients (= 18 years)
•3. confirmed diagnosis of Philadelphia chromosome and / or BCR-ABL1 fusion gene positive chronic myeloid leukaemia (CML)
•4. treatment of CML with a tyrosine kinase inhibitor (TKI) in first-line or multi-line, mono- or combined therapy
•5. intention to discontinue TKI treatment at the time of entry into the register with the aim of treatment-free remission (for the first time or repeated after previous failed discontinuation attempts).
•6. commitment of the participating institution to send all blood samples collected during routine care for the determination of the molecular remission level to the scientific laboratory of the Universitätsmedizin Mannheim for analysis and for the biomaterial database for the duration of the patient's participation in the register. For these samples, the amount of blood to be collected must be increased by 10-30 ml for the scientific analyses.Written informed consent from the patient is required for use in the register.

发起方

niversität Heidelberg